🚀 CapsoVision (NASDAQ: CV) $CV

I’ve been following CapsoVision for quite some time and believe that the company’s story has continued to evolve over the past few months. What’s particularly exciting is that some key milestones are no longer just hopes for the future—they’ve become a reality.

Here’s an overview of the key achievements:

✅ FDA Approval for AI Highlights: On September 25, 2026, CapsoVision received the long-awaited FDA approval for its AI-powered analysis feature. It flags images with potential abnormalities and is designed to help doctors review capsule endoscopy images more efficiently.

🌍 International AI Launch: AI Highlights has already been launched in the EU and other international markets. With FDA approval, the path is now clear for its commercial launch in the U.S.

📈 Revenue Growth: In the second quarter of 2026, revenue rose by approximately 10% to $3.64 million. At the same time, sales of CapsoCam Plus capsules increased by 13% compared to the same quarter last year.

🏥 Over 176,000 patients: By the end of June 2026, CapsoCam Plus had been used in more than 176,000 patients. This demonstrates that a commercial business already exists and that the technology is not merely in the development phase.

🔬 Additional products in the pipeline: With CapsoCam Colon, the company is working on a capsule solution for colon imaging and polyp detection. Additionally, CapsoCam UGI is being investigated as part of the development of new diagnostic options for diseases such as pancreatic cancer.

📅 November is shaping up to be particularly exciting! The next quarterly earnings report is expected in November. For me, the key question will be whether the progress made so far is already reflected in the financial results: Is revenue continuing to grow? How is the business performing following FDA approval? And is there any new information regarding the U.S. market launch and the product pipeline?

What interests me most about this: CapsoVision combines medical technology, capsule endoscopy, and artificial intelligence. FDA approval is an important step—now the company must prove that this will lead to stronger revenue growth and, in the long term, a financially viable business.

⚠️ Of course, risks remain: The company is reporting losses, needs capital, and potential additional stock issuances could dilute existing shareholders. The new products also still need to clear their next development and approval milestones.

💬 What are your thoughts on CapsoVision?

Could the combination of capsule endoscopy and AI become a major growth market in the long term? And what will you be paying particular attention to in the upcoming earnings reports?

#capsovision
#cv
#medtech
#artificialintelligence
#ai
#ki
#healthcare
#smallcaps
#growthstocks
#aktien
#aktienanalyse
#aktieninvestment
#nasdaq
#fda
#endoscopy
#kapselendoskopie
#medicaltechnology
#investieren
#langfristiginvestieren

Today I’d like to write about a stock that probably hasn’t even crossed many of your radars yet. Partly because the current situation is very interesting right now. 👀 $CV

CapsoVision develops capsule endoscopy systemsthat can be used to examine the gastrointestinal tract. What makes it special: The CapsoCam Plus features a 360° panoramic view, requires no external data recorder, and is connected to the cloud-based CapsoCloud platform.

And this is exactly where it gets exciting for me:

🤖 AI + MedTech + Capsule Endoscopy

CapsoVision is developing its own AI solutions designed to assist doctors in evaluating the captured images.

In August, AI Highlights was launched internationally, including in the EU. The software identifies suspicious, clinically relevant images during processing, thereby making the physician’s evaluation more efficient. However, FDA approval is still pending for the U.S.

• And it is precisely this FDA approval that I am currently keeping a close eye on.

• The company now expects FDA approval for AI Highlights by the end of Q3 2026 and plans to launch in the U.S. shortly thereafter.

This could be an important milestone for CapsoVision.

📊 There’s also progress on the operational front:

• Q2 2026 revenue: $3.6 million

• +10% compared to the previous year

• CapsoCam Plus already in use by over 176,000 patients used

• Increasing adoption among large hospital and GI networks

• AI Highlights already available internationally

• CapsoCam Colon as the next major product in the pipeline

• Additional research in the area of pancreatic cancer detection

And yet, the stock is currently far from its all-time high.

📉 Current price: ~$6.60

📈 52-week high: ~$15.37

To me, CapsoVision isn’t a classic “value stock.”

I see it more as a high-risk/high-reward medtech opportunity.

If CapsoVision manages to actually establish its technology as a platform for AI-powered capsule endoscopy, the company could be valued quite differently in a few years.

Are you already familiar with CapsoVision?

🔹 Are you invested?

🔹 What do you think of the AI story?

🔹 How do you assess the chances of FDA approval?

🔹 And most importantly: What would be a fair price for you if AI Highlights is approved in the U.S.?

Maybe someone here knows the company or the industry even better than I do. 👇

I look forward to your thoughts, especially the critical ones.

#capsovision
#cv
#nasdaq
#aktien
#aktienanalyse
#aktiencommunity
#börse
#investieren
#investment
#aktieninvestment
#smallcaps
#smallcapstocks
#growthstocks
#growthinvesting
#medtech
#medtechstocks
#healthcare
#healthcarestocks
#healthcareinvesting
#artificialintelligence
#ai
#ki
#künstlicheintelligenz
#fda
#endoscopy
#kapselendoskopie
#medicaltechnology
#biotech
#usaktien
#wallstreet
#stockmarket
#stockanalysis
#investor
#investing
#getquin
#dividenden
#langfristiginvestieren
#dax
#tech

$CV

I've been following CapsoVision since its IPO, and the last few months have been anything but boring.

What has happened since then?

✅ The company has completed a $14 million capital increase . While this led to some dilution in the short term, it also secured funding for sales, marketing, and further development of the technology.

✅ The Q1 2026 results showed that while CapsoVision is not yet profitable, management continues to invest consistently in growth and the AI-powered endoscopy platform.

✅ For me, the most important driver of the stock price remains the FDA 510(k) clearance of the AI-Assisted Reading Module for CapsoCam Plus. The company is already preparing for commercialization following approval. However, no final decision has been announced to date.

My assessment:

CapsoVision is currently not a value investment, but rather a classic high-risk/high-reward medtech story.

The coming months are likely to be decisive:

📌 FDA decision on the AI module

📌 Commercialization following a potential approval

📌 Revenue growth and acceptance among doctors

I’m staying invested and view the current phase as a test of patience. If the FDA gives the green light and the company successfully markets the technology, 2026 could be a very exciting year. At the same time, the risk remains high if approvals are further delayed or growth falls short of expectations.

I’d be interested to know:

Are you invested in CapsoVision, or are you just watching the stock from the sidelines?

#nasdaq
#medtech
#healthcare
ai
#artificialIntelligence
#growthstocks
#SmallCap
#Investieren
#aktie
#aktien
#börse
#getquin
#investing
#usa

...and finally a post again ;)

$SREN (-0,23%) is a new addition - for me a solid anchor with a stable dividend base and global positioning. Exactly the kind of stock that pays very good dividends in a long-term portfolio.

I have also further increased my position in $CV also increased my position further 🚀

CapsoVision is active in the MedTech sector and develops innovative solutions for endoscopic diagnostics. The market it addresses is huge - at the same time, the company is still relatively unknown and therefore clearly a growth story in my view.

What particularly appeals to me:

- Niche focus with a technological USP

- Scaling potential in the international healthcare market

- Opportunity to establish itself in a specialized segment

- Still under the radar of many investors

Of course, this is not a "safe dividend play", but rather an opportunity-oriented growth case with a higher risk. This is precisely why I currently find the mix of defensive (Swiss Re) and offensive (CapsoVision) exciting.

I would be interested in your opinion:

Do you see real multibagger potential in CapsoVision or is the risk here too high for you?

And who of you is also invested there (Swiss Re, CapsoVision)?

Have a nice Sunday. :)

#swissre
#wachstumsaktien
#medtech
#smallcaps
#aktien
#aktienanalyse
#langfristiginvestieren
#aktiencommunity
#etf
#börse
#dividende

$CV The share price has risen by over 100% recently, boosted by the third quarter results and news of the FDA approval application. Given the strong technical indicators, the rally could continue to +15 US dollars.

#stockanalysis
#etfs
#crypto
#tech
#dividends
#nasdaq
#nyse
#dax
#deutschland
#aktien
#aktie
$NOVO B (+1,44%)
$ONDS (+4,93%)
$BTC (-0,25%)
$ETH (-0,12%)

$CV Really taking off! +26% today. 🚨

What is $CV ? See my last posts. ✨

#börse
#aktien
#investieren
#medical
#nasdaq
#inevstment

CapsoVision $CV continues to show itself to be an exciting MedTech company with ambitions - and the current share price of USD 7.19 reflects the growing interest. 📈

🔎 What's happening right now

• In Q3 2025, CapsoVision reported revenue of USD 3.5 million - a growth of +19% YoY. And the number of new customers increased by 31% compared to the same quarter last year.

• The use of the existing capsule endoscopy technology CapsoCam Plus is working: By the end of Q3, it had already been used on over 151,000 patients.

• At the same time, CapsoVision is pushing ahead with its product pipeline: the company recently submitted an application to the U.S. Food and Drug Administration (FDA) for a capsule for the early detection of pancreatic cancer - with the aim of a "Breakthrough Device Designation".

Who has the share on their watchlist or is also invested?

#medtech
#smallcap
#capsovision
#cv
#capsuleendoscopy
#healthtech
#innovation
#investing
#biotech
#growthpotential
#riskandreward
#aktie
#aktien
#nasdaq
#nyse
#crypto
#börse
#dax

CapsoVision $CV update - 11.11.2025

Today the share is trading at around USD 5.37, which corresponds to a daily performance of around +8.7%.

This shows a positive movement in market sentiment in the short term.

🔜 What's next?

CapsoVision will publish its Q3 figures on November 13, 2025.

For investors, this means increased volatility, as expectations, balance sheet situation, liquidity and outlook will be scrutinized.

• Today's rise in the share price shows that market participants clearly have positive expectations ahead of the figures release.

#aktien
#etf
#usa
#medical
#tech
#dax
#invest
#investieren
#börse
#nyse
#nasdaq

Today I have an exciting position in Ondas Holdings $ONDS (+4,93%) a company that specializes in autonomous autonomous drone systems and mission-critical networks specialized in autonomous drone systems and mission-critical networks. The combination of innovative technology and growing demand for security and infrastructure solutions makes Ondas a real growth champion. I came across the share myself via Getquin.

💡 Why Ondas?

• Focus on autonomous drones and counter-drone systems
• Strong order backlog and growing sales in the drone segment
• Potential to establish itself as a leading provider in niche markets for authorities, defense and critical infrastructure

🔮 Future prospects:

• Further government and industrial orders could greatly accelerate growth
• Expansion of production and service capacities, also internationally
• Possible in the long term: combination of network and drone technologies as complete solutions for mission-critical applications

Important: Ondas combines several relevant areas: not only drones, but also networks + counter-drone. This allows it to offer complete solutions, which some competitors lack, e.g. focusing only on detection or only on hardware.

📈 I see the investment as a growth opportunitythat fits ideally into a diversified portfolio. This alongside $PNG (+2,08%) 🐙 and $CV 💊

#wachstumsaktien
#drohnen
#innovation
#technologie
#missioncritical
#investieren
#aktienliebe
#futuretech
#investieren
#börse
#usa
#deutschland
#nasdaq
#smallcap
#aktien
#technologie
#aktie

On 18.07. I bought shares in CapsoVision at USD 4.76 $CV in my portfolio.

The reason: the company is working on approval of its colon capsule - a product with great market potential in the field of capsule endoscopy. In the IPO prospectus and in analysts' comments, the colon market was described as having greater market potential than the current small intestine segment.

I have calculated three scenarios (example with 1000 shares):

🔹 Conservative (~6 USD): approx. 6,000 USD (+1.2k profit)

🔹 Moderate (~13.5 USD): Approx. 13,500 USD (+8.7k profit)

🔹 Aggressive (~30 USD): Approx. 30,000 USD (+25.2k profit)

Of course, this is not a guarantee, but a look at opportunities that could arise if CapsoVision makes the breakthrough.

👉 It will be particularly exciting to see how quickly the technology is accepted in practice and whether the colon capsule really changes the market.

What do you think? Gamechanger in MedTech or too much risk?

#aktien
#medtech
#wachstumsaktien
#capsovision
#investieren
#longterm
#chancen
#gesundheit
#getquin
#innovation
#börse
#dax
#nyse
#nasdaq
#invest
#medical
#medizin
#tenbagger
#aktie